Interpace Biosciences, Inc. (IDXG)
OTCMKTS · Delayed Price · Currency is USD
1.998
+0.003 (0.13%)
Apr 22, 2026, 1:25 PM EST
Interpace Biosciences Employees
Interpace Biosciences had 102 employees as of December 31, 2025. The number of employees decreased by 9 or -8.11% compared to the previous year.
Employees
102
Change (1Y)
-9
Growth (1Y)
-8.11%
Revenue / Employee
$379,686
Profits / Employee
$240,931
Market Cap
55.40M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 102 | -9 | -8.11% | 102 | 0 |
| Dec 31, 2024 | 111 | 3 | 2.78% | 111 | 0 |
| Dec 31, 2023 | 108 | 14 | 14.89% | 108 | 0 |
| Dec 31, 2022 | 94 | -53 | -36.05% | 94 | 0 |
| Dec 31, 2021 | 147 | -5 | -3.29% | 147 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Centogene | 384 |
| Psychemedics | 101 |
| ProPhase Labs | 96 |
| Longduoduo Company | 52 |
| Aspira Women's Health | 36 |
| IDenta | 16 |
| Hypha Labs | 5 |
Interpace Biosciences News
- 22 days ago - Interpace Biosciences Announces Fourth Quarter and Full Year 2025 Financial and Business Results - GlobeNewsWire
- 5 months ago - Interpace Biosciences Announces Early Repayment of Debt to BroadOak Capital Partners - GlobeNewsWire
- 5 months ago - Interpace Biosciences Announces Third Quarter 2025 Financial and Business Results - GlobeNewsWire
- 7 months ago - Interpace Biosciences Presented Two New Posters at the 2025 American Thyroid Association® (ATA) Annual Meeting - GlobeNewsWire
- 1 year ago - Effective May 2, 2025, Interpace Diagnostics® Will No Longer Accept Specimens for PancraGEN®, a Molecular Diagnostic Test That Assesses Pancreatic Cyst Cancer Risk - GlobeNewsWire
- 1 year ago - Interpace Biosciences Announces Preliminary Full-year and Fourth Quarter 2024 Financial and Business Results - GlobeNewsWire
- 1 year ago - PancraGEN® Will Continue to be Offered While Interpace Re-evaluates its Previously Announced Re-structuring Plan - GlobeNewsWire
- 1 year ago - Effective 02/07/2025, Interpace Diagnostics® to No Longer Offer PancraGEN®, a Molecular Diagnostic Test That Assesses Pancreatic Cyst Cancer Risk - GlobeNewsWire